Back to news
RVURYVU
Parkiet•October 15, 2026 at 07:33 AM

RYVU: Dane przedkliniczne in vivo dla RVU602 – nowej substancji czynnej do ADC – zaprezentowane podczas World ADC Congress 2026 / Preclinical in-vivo data for RVU602, a novel ADC payload, presented at the World ADC Congress 2026

Filing

About this article

  • Article from: Parkiet
  • Concerns: RYVU (RVU)
  • Click the source link to read the full article
Read full article at source

Parkiet.com

Related Stock

RVU

RYVU

Sponsored

Advertisement
Community

Join the discussion on Discord

Connect with investors discussing GPW stocks in real-time.

Join Server